Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rapt Therapeutics Inc (RAPT)

Rapt Therapeutics Inc (RAPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,600,033
  • Shares Outstanding, K 27,711
  • Annual Sales, $ 0 K
  • Annual Income, $ -129,870 K
  • EBIT $ -113 M
  • EBITDA $ -114 M
  • 60-Month Beta 0.47
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.29

Options Overview Details

View History
  • Implied Volatility 18.24% (+3.57%)
  • Historical Volatility 152.01%
  • IV Percentile 8%
  • IV Rank 1.06%
  • IV High 714.82% on 04/17/25
  • IV Low 10.80% on 01/23/26
  • Expected Move (DTE 8) 1.32 (2.28%)
  • Put/Call Vol Ratio 0.29
  • Today's Volume 621
  • Volume Avg (30-Day) 923
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 20,803
  • Open Int (30-Day) 13,804
  • Expected Range 56.40 to 59.04

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.92
  • Number of Estimates 5
  • High Estimate -0.74
  • Low Estimate -1.30
  • Prior Year -9.12
  • Growth Rate Est. (year over year) +89.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.00 +80.38%
on 01/16/26
57.86 -0.24%
on 02/04/26
+24.10 (+71.68%)
since 01/09/26
3-Month
26.50 +117.81%
on 11/21/25
57.86 -0.24%
on 02/04/26
+28.24 (+95.79%)
since 11/11/25
52-Week
5.67 +918.78%
on 05/15/25
57.86 -0.24%
on 02/04/26
+48.36 (+516.67%)
since 02/11/25

Most Recent Stories

More News
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

RAPT : 57.72 (-0.03%)
ALGT : 109.33 (-4.38%)
LSTA : 4.54 (unch)
AVO : 13.66 (-0.36%)
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

RAPT : 57.72 (-0.03%)
ALGT : 109.33 (-4.38%)
LSTA : 4.54 (unch)
AVO : 13.66 (-0.36%)
Halper Sadeh LLC is Investigating Whether NWE, DHIL, RAPT are Obtaining Fair Prices for its Shareholders

Insiders may stand to receive substantial financial benefits that are not available to ordinary shareholders.

RAPT : 57.72 (-0.03%)
DHIL : 171.08 (+0.05%)
NWE : 68.45 (+0.15%)
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of RAPT Therapeutics ...

RAPT : 57.72 (-0.03%)
GSK : 58.49 (-0.56%)
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--JHG, FOLD, RAPT, and EXAS

NEW YORK , Feb. 2, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

FOLD : 14.31 (+0.07%)
EXAS : 103.43 (+0.08%)
RAPT : 57.72 (-0.03%)
JHG : 48.22 (-0.04%)
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm as there may be limited time to enforce your rights.  

RAPT : 57.72 (-0.03%)
LSTA : 4.54 (unch)
PEN : 338.26 (-0.21%)
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTA

NEW YORK , Jan. 28, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

NATH : 100.89 (+0.01%)
RAPT : 57.72 (-0.03%)
LSTA : 4.54 (unch)
PEN : 338.26 (-0.21%)
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of RAPT Therapeutics ...

RAPT : 57.72 (-0.03%)
GSK : 58.49 (-0.56%)
Halper Sadeh LLC Encourages CVGW, RAPT, CFLT Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm as there may be limited time to enforce your rights.  

CFLT : 30.51 (-0.26%)
RAPT : 57.72 (-0.03%)
CVGW : 25.09 (unch)
Stocks Plunge on Greenland Crisis and Soaring Bond Yields

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -2.06%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -1.76%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -2.12%. March E-mini...

MSTR : 126.07 (-5.21%)
GOOGL : 310.96 (-2.39%)
APP : 456.81 (-3.41%)
AAPL : 275.50 (+0.67%)
RRC : 36.38 (+1.59%)
TAP : 53.27 (+2.38%)
HL : 23.69 (+3.09%)
CDE : 23.08 (+1.05%)
GLXY : 20.40 (-3.73%)
BF.B : 30.28 (+1.24%)
COIN : 153.20 (-5.73%)
TSLA : 428.27 (+0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

RAPT Therapeutics Inc. is a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for oncology and inflammatory diseases. The company's drug candidate consists of FLX475 for the treatment of tumors and RPT193,...

See More

Key Turning Points

3rd Resistance Point 57.88
2nd Resistance Point 57.85
1st Resistance Point 57.78
Last Price 57.72
1st Support Level 57.68
2nd Support Level 57.65
3rd Support Level 57.58

See More

52-Week High 57.86
Last Price 57.72
Fibonacci 61.8% 37.92
Fibonacci 50% 31.76
Fibonacci 38.2% 25.60
52-Week Low 5.67

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar